Seko et al. [15] conducted a single-arm prospective study in 20 NAFLD patients for 12 weeks and demonstrated that pemafibrate (0.1 mg) twice a day significantly decreases ALT, GGT, and TG levels and increases the HDL-cholesterol level. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.